June 15, 2017 - By Kurt Siggers
National Pension Service decreased Dte Energy Co (DTE) stake by 2.56% reported in 2016Q4 SEC filing. National Pension Service sold 3,718 shares as Dte Energy Co (DTE)’s stock rose 8.06%. The National Pension Service holds 141,751 shares with $13.96M value, down from 145,469 last quarter. Dte Energy Co now has $19.94 billion valuation. The stock declined 0.39% or $0.43 reaching $110.07 per share. About 355,646 shares traded. DTE Energy Co (NYSE:DTE) has risen 19.61% since June 15, 2016 and is uptrending. It has outperformed by 2.91% the S&P500.
Among 31 analysts covering AstraZeneca PLC (LON:AZN), 15 have Buy rating, 5 Sell and 11 Hold. Therefore 48% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 3700 lowest target. GBX 4924.92’s average target is -6.57% below currents GBX 5271 stock price. AstraZeneca PLC had 486 analyst reports since July 23, 2015 according to SRatingsIntel. HSBC downgraded AstraZeneca plc (LON:AZN) rating on Monday, February 8. HSBC has “Hold” rating and GBX 4880 target. JP Morgan maintained AstraZeneca plc (LON:AZN) on Tuesday, November 17 with “Neutral” rating. As per Wednesday, January 4, the company rating was maintained by JP Morgan. The firm has “Buy” rating given on Wednesday, November 16 by Societe Generale. The rating was maintained by Berenberg with “Buy” on Friday, November 13. The company was maintained on Tuesday, May 23 by Shore Capital. JP Morgan maintained the stock with “Neutral” rating in Tuesday, August 18 report. The stock has “Hold” rating by Nordea on Wednesday, January 13. On Tuesday, April 26 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Hold” rating on Friday, June 2 by Shore Capital. See AstraZeneca plc (LON:AZN) latest ratings:
15/06/2017 Broker: Shore Capital Rating: Hold Maintain
14/06/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 5500.00 New Target: GBX 5500.00 Maintain
12/06/2017 Broker: Shore Capital Rating: Hold Maintain
07/06/2017 Broker: JP Morgan Rating: Neutral Maintain
06/06/2017 Broker: Shore Capital Rating: Hold Maintain
05/06/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 5500.00 New Target: GBX 5500.00 Maintain
05/06/2017 Broker: Goldman Sachs Rating: Sell Maintain
05/06/2017 Broker: Kepler Cheuvreux Rating: Buy Old Target: GBX 5500.00 New Target: GBX 5500.00 Maintain
05/06/2017 Broker: JP Morgan Rating: Neutral Maintain
05/06/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 5700.00 New Target: GBX 5700.00 Maintain
National Pension Service increased United Technologies Corp (NYSE:UTX) stake by 38,991 shares to 553,860 valued at $60.71 million in 2016Q4. It also upped Pepsico Inc (NYSE:PEP) stake by 71,781 shares and now owns 926,165 shares. 3M Co (NYSE:MMM) was raised too.
Since February 13, 2017, it had 1 insider buy, and 8 insider sales for $6.07 million activity. Muschong Lisa A. also sold $46,651 worth of DTE Energy Co (NYSE:DTE) shares. The insider PETERSON BRUCE D sold $550,375. ANDERSON GERARD M also sold $1.67M worth of DTE Energy Co (NYSE:DTE) on Friday, February 17. $982,500 worth of stock was sold by Kurmas Steven E on Tuesday, February 21. 3,800 shares valued at $395,998 were sold by Lauer Trevor F on Tuesday, May 2. Thomas David A bought $65,967 worth of DTE Energy Co (NYSE:DTE) on Monday, February 13. Norcia Gerardo sold 4,838 shares worth $535,717.
Analysts await DTE Energy Co (NYSE:DTE) to report earnings on July, 25. They expect $0.94 EPS, down 4.08% or $0.04 from last year’s $0.98 per share. DTE’s profit will be $170.29M for 29.27 P/E if the $0.94 EPS becomes a reality. After $1.79 actual EPS reported by DTE Energy Co for the previous quarter, Wall Street now forecasts -47.49% negative EPS growth.
Among 6 analysts covering Dte Energy Company (NYSE:DTE), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Dte Energy Company had 14 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was upgraded by Bank of America to “Buy” on Tuesday, November 22. Credit Suisse initiated DTE Energy Co (NYSE:DTE) on Wednesday, January 25 with “Neutral” rating. UBS downgraded DTE Energy Co (NYSE:DTE) on Monday, January 9 to “Neutral” rating. The rating was upgraded by Barclays Capital to “Overweight” on Wednesday, January 13. The firm has “Buy” rating by Jefferies given on Friday, April 28. UBS maintained the shares of DTE in report on Thursday, September 29 with “Buy” rating. The stock of DTE Energy Co (NYSE:DTE) has “Buy” rating given on Monday, November 14 by Jefferies. The stock of DTE Energy Co (NYSE:DTE) earned “Overweight” rating by Barclays Capital on Thursday, April 7.
Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.44, from 1.48 in 2016Q3. It worsened, as 49 investors sold DTE shares while 167 reduced holdings. 60 funds opened positions while 164 raised stakes. 119.36 million shares or 1.43% more from 117.67 million shares in 2016Q3 were reported. Mai owns 0.03% invested in DTE Energy Co (NYSE:DTE) for 4,145 shares. First Bancorp Sioux Falls owns 3,434 shares or 1.37% of their US portfolio. Cleararc Cap Incorporated stated it has 0.08% of its portfolio in DTE Energy Co (NYSE:DTE). Lazard Asset Management Limited Co has 0.03% invested in DTE Energy Co (NYSE:DTE). Dupont Capital Management Corporation holds 0.02% in DTE Energy Co (NYSE:DTE) or 10,569 shares. Keybank Association Oh holds 0.01% or 19,688 shares. New Mexico Educational Retirement Board accumulated 0.09% or 19,146 shares. Allianz Asset Ag stated it has 512,963 shares. Geode Management Lc has 1.65 million shares for 0.08% of their portfolio. Advantus Cap Mgmt reported 39,086 shares. Bluemountain Capital Management Ltd Llc reported 7,762 shares stake. Argi Invest Ser Ltd invested 0.18% in DTE Energy Co (NYSE:DTE). Klingenstein Fields Com Lc accumulated 0.01% or 2,050 shares. Adage Capital Prtn Grp Limited Liability Co accumulated 801,527 shares. Boston Private Wealth Ltd Liability Co has invested 0.02% in DTE Energy Co (NYSE:DTE).
AstraZeneca PLC is a biopharmaceutical company. The company has market cap of 66.71 billion GBP. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 25.1 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.